Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.

Abstract

Background:

The administration of second- or third-generation anti-CD19 chimeric antigen receptor (CAR) T cells has remarkably improved the survival of patients with relapsed or refractory B cell malignancies. However, there are limited clinical results from fourth-generation CAR-T cell therapy, and the factors affecting response rate and survival have not been fully determined.

Methods:

Lymphoma patients with progression or relapse after intensive treatments, including hematopoietic stem cell transplantation, and life expectancy >2 months were enrolled in the study. Peripheral lymphocytes were collected through apheresis, and magnetically selected T cells were lentivirally transduced with a 4th-generation CAR featuring an anti-CD19 CAR and the iCasp9 suicide switch (4SCAR19). The patients received 4SCAR19 T cell infusion after approximately seven days of expansion and a conditioning regimen comprising cyclophosphamide/fludarabine. The efficacy, safety, and risk factors were evaluated.

Results:

A total of 21 patients with relapsed/refractory B cell non-Hodgkin lymphoma were enrolled and received 4SCAR19 T cell infusions at a median dose of 8.9×105 CAR-T cells/kg. The overall response rate was 67% [95% confidence interval (CI), 43 to 85], with 43% of patients achieving a complete response and 24% having a partial response. The overall and complete response rates were 58 and 33% in the diffuse large B-cell lymphoma (DLBCL) group and 78 and 56% in the non-DLBCL group, respectively. The median overall survival was 23.8 months (95% CI, not reached), with a median follow-up of 13.7 months. Factors affecting overall survival were International Prognostic Index (IPI), disease type, and remission status after CAR-T cell treatment. The most common adverse events of grade 3 or 4 during treatment were neutropenia (76%), leukopenia (71%), and thrombocytopenia (29%). The incidence of cytokine release syndrome (CRS) was 14%, and all cases were grade 1. One patient developed grade 3 neurotoxicity. No deaths were attributed to infusion of 4SCAR19 T cells, CRS, or neurotoxicity.

Conclusions:

In this study, patients with relapsed or refractory B cell non-Hodgkin's lymphoma who received 4SCAR19 T cell therapy had durable responses and few of adverse events. The IPI model is suitable for evaluating the prognosis of patients receiving CAR-T cell therapy.

Trial registration:

Chinese Clinical Trial Registry (http://www.chictr.org.cn): ChiCTR-OOC-16007779.

• Authors: Xuan Zhou, Sanfang Tu, Chunsheng Wang, Rui Huang, Lan Deng, Chaoyang Song, Chunyan Yue, Yanjie He, Jilong Yang, Zhao Liang, Anqin Wu, Meifang Li, Weijun Zhou, Jingwen Du, Zhenling Guo, Yongqian Li, Cheng Jiao, Yuchen Liu, Lung-Ji Chang, Yuhua Li
• Journal: Frontiers in immunology (Front Immunol) Vol. 11 Pg. 564099 ( 2020) ISSN: 1664-3224 [Electronic] Switzerland
• PMID: 33329526 (Publication Type: Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 Zhou, Tu, Wang, Huang, Deng, Song, Yue, He, Yang, Liang, Wu, Li, Zhou, Du, Guo, Li, Jiao, Liu, Chang and Li.

Chemical References

• Antigens, CD19
• CD19 molecule, human
• Receptors, Chimeric Antigen

Topics

• Adult
• Aged
• Antigens, CD19 (immunology)
• Cytokine Release Syndrome (etiology)
• Female
• Follow-Up Studies
• Humans
• Immunotherapy, Adoptive (adverse effects, methods)
• Leukopenia (etiology)
• Lymphoma, Large B-Cell, Diffuse (mortality, therapy)
• Male
• Middle Aged
• Neoplasm Recurrence, Local (therapy)
• Neutropenia (etiology)
• Prognosis
• Progression-Free Survival
• Receptors, Chimeric Antigen (immunology)
• Risk Factors
• Survival Rate
• Thrombocytopenia (etiology)